Johnson & Johnson's Kenvue spinoff revives hope that the IPO market may be opening

  • 📰 CNBC
  • ⏱ Reading Time:
  • 17 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 10%
  • Publisher: 72%

United States News News

United States United States Latest News,United States United States Headlines

As welcome as the Kenvue announcement is, it will not by itself turn around the disastrous IPO market, BobPisani writes.

The news that Johnson & Johnson had finally begun a roadshow for its long-awaited Kenvue spinoff elicited some satisfaction among IPO watchers. The key message: this spinoff of J & J's consumer healthcare division is chock full of names familiar to investors and the public: Band-Aid, Aveeno, Johnson's baby shampoo, Tylenol, Listerine and Neutrogena.

It was the biggest tech IPO of 2022, raising $861 million, but the float was only about 5% of the market cap. Corebridge Financial, the biggest IPO last year, floated about 12% of the market capitalization. Spinoffs have become a big business It's not lost on IPO watchers that spinoffs have become a big business.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 12. in US

United States United States Latest News, United States United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

WSJ News Exclusive | J&J Consumer-Health IPO Process to Kick Off Key Test for Moribund New-Issue MarketJohnson & Johnson is set to begin pitching shares of its consumer-healthcare business in a big test for the IPO market
Source: WSJ - 🏆 98. / 63 Read more »